Is Teicoplanin compatible with breastfeeding? Do we have alternatives for Teicoplanin?

Teicoplanin

July 31, 2017 (Very Low Risk)

Antibacterial glycopeptide, administered via intravenous or intramuscular
injection.

Its pharmacokinetic data (high molecular weight, high percentage of plasma protein binding and no oral bioavailability) explain the negligible passage into milk observed (Fraissinet 2017) and the absence of side effects in a 52-day-old infant whose mother was being treated with teicoplanin (Kaplan 2017).

Not being absorbed orally, there would be no passage to the infant's plasma from ingested breast milk.
It is an antibiotic that is administered, if necessary, to newborns.

The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to altered intestinal flora.

Alternatives

We do not have alternatives for Teicoplanin since it is relatively safe.

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Synonyms

  • Teichomycin A2

Writings

  • τεϊκοπλανίνη (Greek)
  • تايكوبلانين (Arabic)
  • Тейкопланин (Cyrillic)
  • 替考拉宁 (Chinese)
  • テイコプラニン (Japanese)

Drug trade names

References

  1. Kaplan YC, Keskin-Arslan E, Acar S, Erol-Coskun H. Teicoplanin Use During Breastfeeding. Breastfeed Med. 2017Abstract
  2. Fraissinet F, Lesourd M, Naudoux N, Metsu D, Gandia P. Pharmacokinetics of Teicoplanin in a Breastfeeding Mother. Breastfeed Med. 2017Abstract
  3. AEMPS. Teicoplanina. Ficha técnica. 2016 Full text (in our servers)
  4. Sanofi. Teicoplanin. Drug Summary. 2009 Full text (in our servers)
  5. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000Abstract